Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
177Lu-P17-088
i
Other names:
177Lu-P17-088
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Five Eleven Pharma, Peking Union Medical College
Drug class:
Ionizing radiation emitter, PSMA inhibitor
Related drugs:
‹
177Lu-satetraxetan-lilotomab (4)
ibritumomab tiuxetan (3)
AAA614 (2)
Actinium-225 conjugated to daratumumab (2)
CLR 131 (2)
PNT2002 (2)
225Ac-FL-020 (1)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-LNC1003 (0)
177Lu-LNC1004 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
TLX66 (0)
iodine I 131 tositumomab (0)
samarium-153 DOTMP (0)
EBTATE (0)
FF21101 (0)
ITM-91 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
186Re (0)
Radspherin (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
Re (0)
lutetium Lu 177 vipivotide tetraxetan (4)
INO-5401 (1)
JNJ-63898081 (1)
AAA817 (0)
AB-2100 (0)
AB001 (0)
ALF501 (0)
CONV01-α (0)
CB307 (0)
CBP-1018 (0)
CC-1 (0)
CCW702 (0)
FPI-2265 (0)
HPN424 (0)
INO-5150 (0)
BIND-014 (0)
177 Lu-FC705 (0)
AMG 160 (0)
G-202 (0)
REGN5678 (0)
BAY 2315497 (0)
177Lu-satetraxetan-lilotomab (4)
ibritumomab tiuxetan (3)
AAA614 (2)
Actinium-225 conjugated to daratumumab (2)
CLR 131 (2)
PNT2002 (2)
225Ac-FL-020 (1)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-LNC1003 (0)
177Lu-LNC1004 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
TLX66 (0)
iodine I 131 tositumomab (0)
samarium-153 DOTMP (0)
EBTATE (0)
FF21101 (0)
ITM-91 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
186Re (0)
Radspherin (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
Re (0)
lutetium Lu 177 vipivotide tetraxetan (4)
INO-5401 (1)
JNJ-63898081 (1)
AAA817 (0)
AB-2100 (0)
AB001 (0)
ALF501 (0)
CONV01-α (0)
CB307 (0)
CBP-1018 (0)
CC-1 (0)
CCW702 (0)
FPI-2265 (0)
HPN424 (0)
INO-5150 (0)
BIND-014 (0)
177 Lu-FC705 (0)
AMG 160 (0)
G-202 (0)
REGN5678 (0)
BAY 2315497 (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer (NCT05603559)
Phase 1
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Completed
Phase 1
Peking Union Medical College Hospital
Completed
Last update posted :
10/23/2023
Initiation :
01/01/2023
Primary completion :
09/05/2023
Completion :
10/04/2023
FOLH1
|
FOLH1 expression • FOLH1 overexpression
|
177Lu-P17-087 • 177Lu-P17-088
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login